Guardant Health (GH) Gained from Better-Than-Expected Results

2 weeks ago 11

Soumya Eswaran

Thu, February 26, 2026 astatine 6:48 AM CST 3 min read

Aristotle Funds, an concern advisor, released its “Growth Equity Fund” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. U.S. equity markets reached caller all-time highs successful Q4 2025, with the S&P 500 Index rising 2.66% and the Bloomberg U.S. Aggregate Bond Index expanding by 1.10%. Within the Russell 1000 Growth Index, healthcare, connection services, and financials were the top-performing sectors, portion utilities, existent estate, and materials lagged. The U.S. system showed resilience. However, user assurance deteriorated toward year-end, raising concerns astir aboriginal spending and the labour market. Against this backdrop, the Aristotle Growth Equity Fund (Class I-2) returned 0.95%, underperforming the Russell 1000 Growth Index’s 1.12%. Poor information enactment successful the accusation exertion and user discretionary sectors detracted from performance, portion affirmative contributions from healthcare and industrials improved comparative performance. In addition, delight cheque the Fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its fourth-quarter 2025 capitalist letter, Aristotle Growth Equity Fund highlighted Guardant Health, Inc. (NASDAQ:GH) arsenic 1 of its starring contributors. Guardant Health, Inc. (NASDAQ:GH) is simply a precision oncology institution that specializes successful a liquid biopsy trial to observe crab from humor samples. On February 25, 2026, Guardant Health, Inc. (NASDAQ:GH) banal closed astatine $95.27 per share. One-month instrumentality of Guardant Health, Inc. (NASDAQ:GH) was -13.77%, and its shares gained 126.24% implicit the past 12 months. Guardant Health, Inc. (NASDAQ:GH) has a marketplace capitalization of $12.373 billion.

Aristotle Growth Equity Fund stated the pursuing regarding Guardant Health, Inc. (NASDAQ:GH) successful its 4th fourth 2025 capitalist letter:

"Guardant Health, Inc. (NASDAQ:GH) contributed to show successful the 4th fourth aft better-than-expected third-quarter net results driven by measurement maturation and quality of an acquisition of a competitor. General marketplace sentiment successful the manufacture has been improving passim the twelvemonth arsenic concern momentum grows."

Guardant Health, Inc. (NASDAQ:GH) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 62 hedge money portfolios held Guardant Health, Inc. (NASDAQ:GH) astatine the extremity of the 4th quarter, up from 50 successful the erstwhile quarter. In Q4 2025, Guardant Health, Inc. (NASDAQ:GH) delivered astir $281 cardinal successful gross marking 39% year-over-year growth. While we admit the imaginable of Guardant Health, Inc. (NASDAQ:GH) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article